Sabin vaccine reversion in the field: A comprehensive analysis of Sabin-like poliovirus isolates in Nigeria

Journal of Virology

Volumn 90, Issue 1, 2016, Pages 317-331

  Famulare, Michael ^a   Chang, Stewart ^a   Iber, Jane ^b   Zhao, Kun ^b   Adeniji, Johnson A ^c   Bukbuk, David ^d   Baba, Marycelin ^d   Behrend, Matthew ^e   Burns, Cara C ^b   Steven Oberste, M ^b  

^a INSTITUTE FOR DISEASE MODELING   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c UNIVERSITY OF IBADAN   (Nigeria)

^d UNIVERSITY OF MAIDUGURI   (Nigeria)

^e Independent Researcher   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL POLIOMYELITIS VACCINE; PROTEIN VP1; CAPSID PROTEIN; VIRUS RNA; VP1 PROTEIN, POLIOVIRUS;

AMINO ACID SUBSTITUTION; ARTICLE; CHILD; CONTROLLED STUDY; ENTEROVIRUS; FLACCID PARALYSIS; GENE SEQUENCE; GENETIC RECOMBINATION; HUMAN; INFANT; MOLECULAR CLOCK; MOLECULAR EVOLUTION; NIGERIA; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REVERTANT; VIRUS ISOLATION; VIRUS RECOMBINANT; VIRUS STRAIN; VIRUS TRANSMISSION; WILD TYPE; FEMALE; GENETICS; ISOLATION AND PURIFICATION; MALE; MOLECULAR EPIDEMIOLOGY; MUTATION RATE; NEWBORN; PHYLOGENY; POINT MUTATION; PRESCHOOL CHILD; SEQUENCE HOMOLOGY; TIME FACTOR; VIROLOGY; VIRULENCE;

CAPSID PROTEINS; CHILD; CHILD, PRESCHOOL; EVOLUTION, MOLECULAR; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MOLECULAR EPIDEMIOLOGY; MUTATION RATE; NIGERIA; PHYLOGENY; POINT MUTATION; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; RNA, VIRAL; SEQUENCE HOMOLOGY; TIME FACTORS; VIRULENCE;

EID: 84953877610     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01532-15     Document Type: Article

References (70)

1. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. 2005. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 59:587-635. http://dx.doi.org/10.1146/annurev.micro.58.030603.123625.
2. Chumakov K, Ehrenfeld E, Wimmer E, Agol VI. 2007. Vaccination against polio should not be stopped. Nat Rev Microbiol 5:952-958. http://dx.doi.org/10.1038/nrmicro1769.
3. Sutter RW, Maher C. 2006. Mass vaccination campaigns for polio erad-ication: an essential strategy for success. Curr Top Microbiol Immunol 304:195-220.
4. World Health Organization. 2012. Progress towards global interruption of wild poliovirus transmission, January 2011-March 2012. Wkly Epidemiol Rec 87:195-200.
5. Sutter RW, Kew OM, Cochi S, Aylward B. 2013. Poliovirus vaccine-live, p 598-645. In Plotkin, SA, Orenstein, W, Offit, PA (ed), Vaccines, 6th ed. Elsevier, Philadelphia, PA.
6. Benyesh-Melnick M, Melnick JL, Rawls WE, Wimberly I, Oro JB, Ben-Porath E, Rennick V. 1967. Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. Am J Epidemiol 86:112-136.
7. Chen RT, Hausinger S, Dajani AS, Hanfling M, Baughman AL, Pallansch MA, Patriarca PA. 1996. Seroprevalence of antibody against poliovirus in inner-city preschool children. JAMA 275:1639-1645. http://dx.doi.org/10.1001/jama.1996.03530450029028.
8. Wassilak S, Pate MA, Wannemuehler K, Jenks J, Burns CC, Chenoweth P, Abanida EA, Adu F, Baba M, Gasasira A, Iber J, Mkanda P, Williams A, Shaw JJ, Pallansch MA, Kew OM. 2011. Outbreak of type 2 vaccinederived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. J Infect Dis 203:898-909. http://dx.doi.org/10.1093/infdis/jiq140.
9. Jorba J, Campagnoli R, De L, Kew OM. 2008. Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range. J Virol 82:4429-4440. http://dx.doi.org/10.1128/JVI.02354-07.
10. Evans DM, Dunn G, Minor PD, Schild GC, Cann AJ, Stanway G, Almond JW, Currey K, Maizel JV. 1985. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature 314:548-550. http://dx.doi.org/10.1038/314548a0.
11. Minor PD, John A, Ferguson M, Icenogle JP. 1986. Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee. J Gen Virol 67:693-706. http://dx.doi.org/10.1099/0022-1317-67-4-693.
12. Laassri M, Lottenbach K, Belshe R, WolffM, Rennels M, Plotkin S, Chumakov K. 2005. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J Infect Dis 192:2092-2098. http://dx.doi.org/10.1086/498172.
13. El-Sayed N, Yehia E-G, Abbassy A-A, Seoud I, Salama M, Kandeel A, Hossny E, Shawky A, Hussein HA, Pallansch MA, van der Avoort HGAM, Burton AH, Sreevatsava M, Malankar P, Wahdan MH, Sutter RW. 2008. Monovalent type 1 oral poliovirus vaccine in newborns. NEngl J Med 359:1655-1665. http://dx.doi.org/10.1056/NEJMoa0800390.
14. van der Sanden S, Pallansch MA, van de Kassteele J, El-Sayed N, Sutter RW, Koopmans M, van der Avoort HG. 2009. Shedding of vaccine viruses with increased antigenic and genetic divergence after vaccination of newborns with monovalent type 1 oral poliovirus vaccine. J Virol 83: 8693-8704. http://dx.doi.org/10.1128/JVI.02388-08.
15. Abraham R, Minor P, Dunn G, Modlin JF, Ogra PL. 1993. Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine. J Infect Dis 168:1105-1109. http://dx.doi.org/10.1093/infdis/168.5.1105.
16. Agol V. 2006. Molecular mechanisms of poliovirus variation and evolution. Curr Top Microbiol Immunol 299:211-259.
17. Kew OM, Wright PF, Agol V, Delpeyroux F, Shimizu H, Nathanson N, Pallansch MA. 2004. Policy and practice circulating vaccine-derived polioviruses: current state of knowledge. Bull World Health Organ 82:16-23.
18. Savolainen-Kopra C, Blomqvist S. 2010. Mechanisms of genetic variation in polioviruses. Rev Med Virol 20:358-371. http://dx.doi.org/10.1002/rmv.663.
19. Burns CC, Shaw J, Jorba J, Bukbuk D, Adu F, Gumede N, Pate MA, Abanida EA, Gasasira A, Iber J, Chen Q, Vincent A, Chenoweth P, Henderson E, Wannemuehler K, Naeem A, Umami RN, Nishimura Y, Shimizu H, Baba M, Adeniji A, Williams AJ, Kilpatrick DR, Oberste MS, Wassilak SG, Tomori O, Pallansch MA, Kew O. 2013. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J Virol 87:4907-4922. http://dx.doi.org/10.1128/JVI.02954-12.
20. Jiang P, Faase JAJ, Toyoda H, Paul A, Wimmer E, Gorbalenya AE. 2007. Evidence for emergence of diverse polioviruses from C-cluster coxsackieA viruses and implications for global poliovirus eradication. Proc Natl Acad Sci U S A 104:9457-9462. http://dx.doi.org/10.1073/pnas.0700451104.
21. Combelas N, Holmblat B, Joffret M-L, Colbère-Garapin F, Delpeyroux F. 2011. Recombination between poliovirus and coxsackie A viruses of species C: a model of viral genetic plasticity and emergence. Viruses 3:1460-1484. http://dx.doi.org/10.3390/v3081460.
22. Jegouic S, Joffret M-L, Blanchard C, Riquet FB, Perret C, Pelletier I, Colbere-Garapin F, Rakoto-Andrianarivelo M, Delpeyroux F. 2009. Recombination between polioviruses and co-circulating coxsackie A viruses: role in the emergence of pathogenic vaccine-derived polioviruses. PLoS Pathog 5:e1000412. http://dx.doi.org/10.1371/journal.ppat.1000412.
23. Duintjer Tebbens RJ, Pallansch MA, Kim J-H, Burns CC, Kew OM, Oberste MS, Diop OM, Wassilak SGF, Cochi SL, Thompson KM. 2013. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal 33: 680-702. http://dx.doi.org/10.1111/risa.12022.
24. Agol V, Belov G, Cherkasova E. 2001. Some problems of molecular biology of poliovirus infection relevant to pathogenesis, viral spread and evolution, p 43-50. In Progress in polio eradication: vaccine strategies for the end game. S. Karger AG, Basel, Switzerland.
25. Zhang Y, Zhang F, Zhu S, Chen L, Yan D, Wang D, Tang R, Zhu H, Hou X, An H, Zhang H, Xu W. 2010. A Sabin 2-related poliovirus recombinant contains a homologous sequence of human enterovirus species C in the viral polymerase coding region. Arch Virol 155:197-205. http://dx.doi.org/10.1007/s00705-009-0564-9.
26. Minor PD, Ferguson M, Evans DM, Almond JW, Icenogle JP. 1986. Antigenic structure of polioviruses of serotypes 1, 2 and 3. J Gen Virol 67(Pt 7):1283-1291. http://dx.doi.org/10.1099/0022-1317-67-7-1283.
27. Behrend MR, Hu H, Nigmatulina KR, EckhoffP. 2014. A quantitative survey of the literature on poliovirus infection and immunity. Int J Infect Dis 18:4-13. http://dx.doi.org/10.1016/j.ijid.2013.09.005.
28. World Health Organization. 2004. Polio laboratory manual, 4th ed. World Health Organization, Geneva, Switzerland.
29. Centers for Disease Control and Prevention. 2010. Progress toward poliomyelitis eradication-Nigeria, January 2009-June 2010. MMWR Morb Mortal Wkly Rep 59:802-807.
30. Centers for Disease Control and Prevention. 2011. Progress toward poliomyelitis eradication-Nigeria, January 2010-June 2011. MMWR Morb Mortal Wkly Rep 60:1053-1057.
31. Centers for Disease Control and Prevention. 2012. Progress toward poliomyelitis eradication-Nigeria, January 2011-September 2012. MMWR Morb Mortal Wkly Rep 61:899-904.
32. Kilpatrick DR, Yang C-F, Ching K, Vincent A, Iber J, Campagnoli R, Mandelbaum M, De L, Yang S-J, Nix A, Kew OM. 2009. Rapid group-, serotype-, and vaccine strain-specific identification of poliovirus isolates by real-time reverse transcription-PCR using degenerate primers and probes containing deoxyinosine residues. J Clin Microbiol 47:1939-1941. http://dx.doi.org/10.1128/JCM.00702-09.
33. Kilpatrick DR, Ching K, Iber J, Chen Q, Yang S-J, De L, Williams AJ, Mandelbaum M, Sun H, Oberste MS, Kew OM. 2014. Identification of vaccine-derived polioviruses using dual-stage real-time RT-PCR. J Virol Methods 197:25-28. http://dx.doi.org/10.1016/j.jviromet.2013.11.017.
34. Kilpatrick D, Iber J, Chen Q, Ching K, Yang S, De L, Mandelbaum MD, Emery B, Campagnoli R, Burns C, Kew OM. 2011. Poliovirus serotypespecific VP1 sequencing primers. J Virol Methods 174:128-130. http://dx.doi.org/10.1016/j.jviromet.2011.03.020.
35. Langmead B, Trapnell C, Pop M, Salzberg SL. 2009. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 10:R25. http://dx.doi.org/10.1186/gb-2009-10-3-r25.
36. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. 2009. The sequence alignment/Map format and SAMtools. Bioinformatics 25:2078-2079. http://dx.doi.org/10.1093/bioinformatics/btp352.
37. Koboldt DC, Chen K, Wylie T, Larson DE, McLellan MD, Mardis ER, Weinstock GM, Wilson RK, Ding L. 2009. VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics 25:2283-2285. http://dx.doi.org/10.1093/bioinformatics/btp373.
38. Kilpatrick D, Nottay B, Yang C-F, Yang S, Da Silva E, Peñaranda S, Pallansch MA, Kew OM. 1998. Serotype-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy. J Clin Microbiol 36:352-357.
39. Wagner BG, Behrend MR, Klein DJ, Upfill-Brown AM, EckhoffPA, Hu H. 2014. Quantifying the impact of expanded age group campaigns for polio eradication. PLoS One 9:e113538. http://dx.doi.org/10.1371/journal.pone.0113538.
40. Mangal TD, Aylward RB, Mwanza M, Gasasira A, Abanida E, Pate MA, Grassly NC. 2014. Key issues in the persistence of poliomyelitis in Nigeria: a case-control study. Lancet Glob Health 2:e90-e97. http://dx.doi.org/10.1016/S2214-109X(13)70168-2.
41. Alexander JP, Gary HE, Pallansch MA. 1997. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J Infect Dis 175(Suppl):S176-S182. http://dx.doi.org/10.1093/infdis/175.Supplement_1.S176.
42. Neverov A, Chumakov K. 2010. Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines. Proc Natl Acad Sci U S A 107:20063-20068. http://dx.doi.org/10.1073/pnas.1012537107.
43. Platt LR, Estívariz CF, Sutter RW. 2014. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis 210(Suppl):S380-S389. http://dx.doi.org/10.1093/infdis/jiu184.
44. Wallace GS, Oberste MS. 2013. Poliomyelitis, p 12.1-12.9. In Roush SW, Baldy LM (ed), Manual for the surveillance of vaccine-preventable diseases. Centers for Disease Control and Prevention, Atlanta, GA.
45. Georgescu MM, Balanant J, Macadam A, Otelea D, Combiescu M, Combiescu A, Crainic R, Delpeyroux F. 1997. Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. J Virol 71:7758-7768.
46. Ogra PL, Faden HS, Abraham R, Duffy LC, Sun M, Minor PD. 1991. Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines. J Infect Dis 164:191-194. http://dx.doi.org/10.1093/infdis/164.1.191.
47. Martinez CV, Old MO, Kwock DK, Khan SS, Garcia JJ, Chan CS, Webster R, Falkovitz-Halpern MS, Maldonado YA. 2004. Shedding of Sabin poliovirus type 3 containing the nucleotide 472 uracil-to-cytosine point mutation after administration of oral poliovirus vaccine. J Infect Dis 190:409-416. http://dx.doi.org/10.1086/421703.
48. Muzychenko AR, Lipskaya GY, Maslova SV, Svitkin YV, Pilipenko EV, Nottay BK, Kew OM, Agol VI. 1991. Coupled mutations in the 5'-untranslated region of the Sabin poliovirus strains during in vivo passages: structural and functional implications. Virus Res 21:111-122. http://dx.doi.org/10.1016/0168-1702(91)90002-D.
49. Macadam AJ, Arnold C, Howlett J, John A, Marsden S, Taffs F, Reeve P, Hamada N, Wareham K, Almond J. 1989. Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. Virology 172:408-414. http://dx.doi.org/10.1016/0042-6822(89)90183-9.
50. Westrop GD, Wareham KA, Evans DM, Dunn G, Minor PD, Taffs F, Marsden S, Skinner MA, Schild GC. 1989. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol 63:1338-1344.
51. Tatem JM, Weeks-Levy C, Georgiu A, DiMichele SJ, Gorgacz EJ, Racaniello VR, Cano FR, Mento SJ. 1992. A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating. J Virol 66: 3194-3197.
52. Chumakov KM, Norwood LP, Parker ML, Dragunsky EM, Ran YX, Levenbook IS. 1992. RNA sequence variants in live poliovirus vaccine and their relation to neurovirulence. J Virol 66:966-970.
53. Cann AJ, Stanway G, Hughes PJ, Minor PD, Evans DMA, Schild GC, Almond JW. 1984. Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Res 12:7787-7792. http://dx.doi.org/10.1093/nar/12.20.7787.
54. Nomoto A, Omata T, Toyoda H, Kuge S, Horie H, Kataoka Y, Genba Y, Nakano Y, Imura N. 1982. Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. Proc Natl Acad Sci U S A 79:5793-5797. http://dx.doi.org/10.1073/pnas.79.19.5793.
55. Odoom JK, Yunus Z, Dunn G, Minor PD, Martín J. 2008. Changes in population dynamics during long-term evolution of Sabin type 1 poliovirus in an immunodeficient patient. J Virol 82:9179-9190. http://dx.doi.org/10.1128/JVI.00468-08.
56. Christodoulou C, Colbere-Garapin F, Macadam AJ, Taffs LF, Marsden S, Minor P, Horaud F. 1990. Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. J Virol 64:4922-4929.
57. Ren RB, Moss EG, Racaniello VR. 1991. Identification of two determinants that attenuate vaccine-related type 2 poliovirus. J Virol 65:1377-1382.
58. Minor PD, John A, Ferguson M, Icenogle JP. 1986. Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee. J Gen Virol 67(Pt 4):693-706. http://dx.doi.org/10.1099/0022-1317-67-4-693.
59. Vignuzzi M, Stone JKJ, Arnold JJ, Cameron CE, Andino R. 2006. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439:344-348. http://dx.doi.org/10.1038/nature04388.
60. Lauring AS, Andino R. 2010. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog 6:e1001005. http://dx.doi.org/10.1371/journal.ppat.1001005.
61. Pfeiffer JK. 2010. Innate host barriers to viral trafficking and population diversity: lessons learned from poliovirus. Adv Virus Res 77:85-118. http://dx.doi.org/10.1016/B978-0-12-385034-8.00004-1.
62. Vignuzzi M, Wendt E, Andino R. 2008. Engineering attenuated virus vaccines by controlling replication fidelity. Nat Med 14:154-161. http://dx.doi.org/10.1038/nm1726.
63. Pfeiffer JK, Kirkegaard K. 2005. Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice. PLoS Pathog 1:e11. http://dx.doi.org/10.1371/journal.ppat.0010011.
64. Glezen WP, McCollough RH, Lamb GA, Chin TDY. 1969. Quantitative relationship of preexisting homotypic antibodies to excretion of poliovirus types 1, 2 and 3 following the feeding of trivalent attenuated poliovirus vaccine. Am J Epidemiol 90:146-156.
65. Ogra PL. 1995. Comparative evaluation of immunization with live attenuated and inactivated poliovirus vaccines. Ann N Y Acad Sci 754:97-107. http://dx.doi.org/10.1111/j.1749-6632.1995.tb44442.x.
66. O'Ryan M, Bandyopadhyay AS, Villena R, Espinoza M, Novoa J, Weldon WC, Oberste MS, Self S, Borate BR, Asturias EJ, Clemens R, Orenstein W, Jimeno J, Rüttimann R, Costa Clemens SA. 26 August 2015. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. Lancet Infect Dis. http://dx.doi.org/10.1016/S1473-3099(15)00219-4.
67. Cuervo N, Guillot S. 2001. Genomic features of intertypic recombinant Sabin poliovirus strains excreted by primary vaccinees. J Virol 75:5740-5751. http://dx.doi.org/10.1128/JVI.75.13.5740-5751.2001.
68. Brown B, Oberste MS, Maher K, Pallansch MA. 2003. Complete genomic sequencing shows that polioviruses and members of human enterovirus species C are closely related in the noncapsid coding region. J Virol 77:8973-8984. http://dx.doi.org/10.1128/JVI.77.16.8973-8984.2003.
69. Georgescu MM, Delpeyroux F, Tardy-Panit M, Balanant J, Combiescu M, Combiescu A, Guillot S, Crainic R. 1994. High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis. J Virol 68:8089-8101.
70. Pfeiffer JK, Kirkegaard K. 2006. Bottleneck-mediated quasispecies restriction during spread of an RNA virus from inoculation site to brain. Proc Natl Acad Sci U S A 103:5520-5525. http://dx.doi.org/10.1073/pnas.0600834103.